COLLABORATIONS
Innovation Pharma has collaborated with researchers at leading teaching hospitals and academic institutions. Innovation Pharma remains engaged in pursuing such collaborations, as well as other strategic partnerships and licensing transactions with interested parties.
On July 22, 2019, Innovation Pharma completed a license agreement with Alfasigma S.p.A, granting the company exclusive rights to develop and commercialize locally-administered Brilacidin (e.g., foam, enema, gel), on a worldwide basis, for the treatment of Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS) in Inflammatory Bowel Disease (IBD).
On July 22, 2020, Innovation Pharma announced the Company granted licensing rights to Fox Chase Chemical Diversity Center, Inc. (FCCDC) for antifungal technology, making it eligible to receive a six (6) percent fee tied to all potential future proceeds—including upfront payments, milestone payments and royalties. FCCDC has since licensed the antifungal technology to Basilea Pharmaceutica AG.
